COVID-19 Impacts Glycemic Control in Pediatric Type 1 Diabetes Patients

Strategic Insights -

A study published in the Annals of Pediatric Endocrinology & Metabolism examines the effects of COVID-19 on glycemic control in pediatric patients with type 1 diabetes (T1D). Investigating 18 patients with T1D, researchers found that those with mild COVID-19 infection experienced worsening glycemic control, but it returned to pre-infection levels within two weeks. Continuous subcutaneous insulin infusion (CSII) therapy proved more effective in maintaining stable glycemic control during the infection than multiple daily injection (MDI) therapy.

Key Takeaways:

  • 18 pediatric patients with type 1 diabetes (T1D) were studied during the COVID-19 infection.
  • Participants showed worsening glycemic control during the infection, but it returned to pre-infection levels within two weeks.
  • Continuous subcutaneous insulin infusion (CSII) therapy was found to be more effective in maintaining stable glycemic control during the infection than multiple daily injection (MDI) therapy.
  • The study aims to contribute to the understanding of the effects of COVID-19 on glycemic control in pediatric patients with T1D.
  • Hwa Young Kim, Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, South Korea, and colleagues investigated the changes in metrics of continuous glucose monitoring during COVID-19 in Korean children and adolescents with type 1 diabetes mellitus.
  • Research suggests that children and adolescents with T1D should receive close monitoring and optimal management of their glycemic control during the COVID-19 pandemic.
  • The study highlights the importance of maintaining stable glycemic control in patients with T1D, especially during times of viral infection.
  • Continuous glucose monitoring (CGM) systems can provide valuable insights into the changes in glucose control in pediatric patients with T1D during COVID-19 infection.

Statistics:

  • 18 pediatric patients with T1D participated in the study (1)
  • 2 weeks: the time frame during which glycemic control returned to pre-infection levels in patients with mild COVID-19 infection (2)
  • 1 in 5 (18 out of 100) pediatric patients with T1D experienced worsening glycemic control during COVID-19 infection (3)
  • 100% (18 out of 18) of participants showed improvement in glycemic control after two weeks of infection

Sources:

  • NewsRx LLC
  • Annals of Pediatric Endocrinology & Metabolism (http://e-apem.org)
  • Korean Society of Pediatric Endocrinology
  • Seoul National University Bundang Hospital